Dual Immunotherapy Avoids Surgery in 70.6% of MSI-H Gastric Cancer Patients
Jun 04, 2026
Dual immunotherapy allowed 70.6% of MSI-H gastric cancer patients to avoid surgery in the INFINITY trial. German off-label immunotherapy shows 20-25% response rates, requiring careful patient selection.